Stock OVXA OVOCA BIO PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ovoca Bio plc

Equities

OVXA

IE00B4XVDC01

Biotechnology & Medical Research

Market Closed - Irish S.E.
Other stock markets
 11:55:00 2024-04-26 am EDT 		5-day change 1st Jan Change
0.006 EUR 0.00% Intraday chart for Ovoca Bio plc 0.00% -40.00%
2021 Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 6.688 8.564 9.706 7.749 12.23 4.894
Enterprise Value (EV) 1 1.139 7.73 -0.3689 -2.997 5.641 1.191
P/E ratio -17.4 x -3.64 x -6.19 x -3.31 x -2.23 x -0.87 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -0.88 x -3.97 x 0.16 x 1.4 x -0.98 x -0.33 x
EV / FCF -1.23 x -8.58 x 0.2 x 2.23 x -2.13 x -0.49 x
FCF Yield -81.3% -11.7% 509% 44.8% -46.9% -204%
Price to Book 0.3 x 0.46 x 0.43 x 0.42 x 0.91 x 0.64 x
Nbr of stocks (in thousands) 81,564 81,564 81,564 81,564 81,564 81,564
Reference price 2 0.0820 0.1050 0.1190 0.0950 0.1500 0.0600
Announcement Date 5/25/18 6/20/19 6/26/20 6/24/21 6/30/22 6/30/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -1.293 -1.947 -2.241 -2.134 -5.776 -3.617
EBIT 1 -1.33 -1.949 -2.315 -2.205 -5.86 -3.967
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -0.381 -1.996 -1.902 -2.318 -5.247 -5.612
Net income 1 -0.381 -2.356 -1.569 -2.336 -5.475 -5.612
Net margin - - - - - -
EPS 2 -0.004700 -0.0289 -0.0192 -0.0287 -0.0671 -0.0688
Free Cash Flow 1 -0.9261 -0.9014 -1.879 -1.343 -2.644 -2.43
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/25/18 6/20/19 6/26/20 6/24/21 6/30/22 6/30/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 5.55 0.83 10.1 10.7 6.59 3.7
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.93 -0.9 -1.88 -1.34 -2.64 -2.43
ROE (net income / shareholders' equity) -1.66% -9.28% -8.56% -10.9% -32.8% -53.3%
ROA (Net income/ Total Assets) -3.6% -5.51% -6.28% -6.37% -21.7% -20.5%
Assets 1 10.57 42.79 24.98 36.7 25.27 27.36
Book Value Per Share 2 0.2700 0.2300 0.2700 0.2300 0.1600 0.0900
Cash Flow per Share 2 0.0700 0.0200 0.1200 0.1300 0.0800 0.0500
Capex - - - 0.01 0.01 -
Capex / Sales - - - - - -
Announcement Date 5/25/18 6/20/19 6/26/20 6/24/21 6/30/22 6/30/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
OVOCA BIO PLC Stock Ovoca Bio plc
-40.00% 522K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OVXA Stock
  4. Financials Ovoca Bio plc